Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · see citing works

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,355 · see citing works

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767 · see citing works

Modelling for Survival Data in Medical Research

(1995) · Technometrics · doi:10.1080/00401706.1995.10485920 · Cited by 2,159 · see citing works

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N. K., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J. J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,889 · see citing works

Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

Marty, M. E., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S. Y. T., Grimes, D., Antón, A., Lluch, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,588 · see citing works

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Smith, I., Procter, M. J., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,503 · see citing works

USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2

Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199 · see citing works

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,170 · see citing works

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobágyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,139 · see citing works

Modelling Survival Data in Medical Research.

McLachlan, G. J., & Collett, D. (1994) · Biometrics · doi:10.2307/2533471 · Cited by 1,023 · see citing works

Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27

Bear, H. D., Anderson, S., Smith, R. E., Geyer, C. E., Mamounas, E. P., Fisher, B., Brown, A. M., Robidoux, A., Margolese, R. G., Kahlenberg, M. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1665 · Cited by 943 · see citing works

Minimization: A new method of assigning patients to treatment and control groups

Taves, D. R. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974155443 · Cited by 891 · see citing works

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

Tan-Chiu, E., Yothers, G., Romond, E. H., Geyer, C. E., Ewer, M. S., Keefe, D. L., Shannon, R. P., Swain, S. M., Brown, A. M., Fehrenbacher, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4091 · Cited by 801 · see citing works

Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute

Hance, K. W., Anderson, W. F., Devesa, S. S., Young, H. A., & Levine, P. H. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji172 · Cited by 687 · see citing works

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.

Bonadonna, G., Valagussa, P., Brambilla, C., Ferrari, L., Moliterni, A., Terenziani, M., & Zambetti, M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.93 · Cited by 565 · see citing works

Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

Slamon, D., EIERMANN, W., Robert, N. J., Pieńkowski, T., Martín, M., Rolski, J., Chan, A., Mackey, J. R., Liu, M., Pintér, T., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-62 · Cited by 553 · see citing works

Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial

Perez, E. A., Suman, V. J., Davidson, N. E., Sledge, G. W., Kaufman, P. A., Hudis, C. A., Martino, S., Gralow, J. R., Dakhil, S. R., Ingle, J. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5467 · Cited by 537 · see citing works

Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule

Baselga, J. M., Carbonell, X., Castañeda-Soto, N.-J., Clemens, M., Green, M., Harvey, V. J., Morales, S. M., Barton, C. M., & Ghahramani, P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.014 · Cited by 423 · see citing works

Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer

Gianni, L., Baselga, J. M., EIERMANN, W., Porta, V. G., Семиглазов, В. Ф., Lluch, A. M., Zambetti, M., Sabadell, D., Raab, G., Llombart‐Cussac, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2567 · Cited by 219 · see citing works

Breast carcinoma survival in Europe and the United States

Sant, M., Allemani, C., Berrino, F., et al. (2004) · Cancer · doi:10.1002/cncr.20038 · Cited by 208 · see citing works

Locally Advanced and Inflammatory Breast Cancer

Chia, S., Swain, S. M., Byrd, D. R., & Mankoff, D. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.15.0243 · Cited by 180 · see citing works

National Surgical Adjuvant Breast and Bowel Project

Fisher, B. (2005) · Encyclopedia of Biostatistics · doi:10.1002/0470011815.b2a01039 · Cited by 167 · see citing works

Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry

Zell, J. A., Tsang, W. Y., Taylor, T. H., Mehta, R. S., & Anton‐Culver, H. (2009) · Breast Cancer Research · doi:10.1186/bcr2225 · Cited by 105 · see citing works

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan

Sharma, S., Kemeny, N. E., Kelsen, D. P., Ilson, D. H., O'Reilly, E. M., Zaknoen, S. L., Baum, C. M., Statkevich, P., Hollywood, E. M., Zhu, Y., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf173 · Cited by 103 · see citing works

Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer

Gianni, L., Dombernowsky, P., Sledge, G. W., Martin, M., Amadori, D., Arbuck, S. G., Ravdin, P. M., Brown, M., MESSINA, M. E., Tuck, D. P., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011655503511 · Cited by 78 · see citing works

Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.

Bianchi, G., Albanell, J., EIERMANN, W., et al. (2003) · PubMed · Cited by 53 · see citing works

Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis

Gianni, L., Семиглазов, В. Ф., Manikhas, G. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.532 · Cited by 35 · see citing works

Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”

Untch, M., Rezai, M., Loibl, S., et al. (2008) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(08)70313-6 · Cited by 27 · see citing works

2030 ORAL Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (NeOAdjuvant Herceptin) Phase III trial

Baselga, J., Семиглазов, В. Ф., Manikhas, G. M., et al. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)70792-9 · Cited by 26 · see citing works

A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: Response and cardiotoxicity

Chang, H., Slamon, D., Prati, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.10515 · Cited by 23 · see citing works

XeNA: Capecitabine Plus Docetaxel, With or Without Trastuzumab, as Preoperative Therapy for Early Breast Cancer

Glück, S., Mckenna, E. F., & Royce, M. (2008) · International Journal of Medical Sciences · doi:10.7150/ijms.5.341 · Cited by 16 · see citing works

Hormone-receptor status and likelihood of predicting pathological complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)

EIERMANN, W., Baselga, J., Семиглазов, В. Ф., et al. (2008) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(08)70544-5 · Cited by 6 · see citing works

Activité biologique des différentes zones obtenues par ultracentrifugation du facteur lacté de la souche de souris PS sur gradients préformés de Ficoll

Mouriquand, J., Mouriquand, C., & Viala, C. (1970) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(70)90008-3 · Cited by 2 · see citing works

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048 · see citing works

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

Hellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70334-6 · Cited by 646 · see citing works

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70329-7 · Cited by 351 · see citing works

Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer

Vera-Badillo, F. E., Shapiro, R., Ocana, A., Amir, E., & Tannock, I. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mds636 · Cited by 117 · see citing works

Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies

Li, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33282-0 · Cited by 80 · see citing works

A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting

McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66 · see citing works

Is there any cumulative dose for trastuzumab?

Mutlu, H., & Çoşkun, H. Ş. (2014) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155214538686 · Cited by 3 · see citing works

Mechanisms of Trastuzumab Resistance and Their Clinical Implications

Lan, K., Lu, C., & Yu, D. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1339.026 · Cited by 75 · see citing works

Cardiac toxicity of trastuzumab in elderly patients with breast cancer

Andrea, A., Denegri, Tiziano, et al. (2016) · 老年心脏病学杂志：英文版

Cytotoxic Effects of Seleno-Trastuzumab, Trastuzumab (Herceptin) and T-DM-1 (Kadcyla) on Trastuzumab Resistant JIMT-1 Breast Cancer Cells

Bapat, P., Boylan, M., Cobos, E., et al. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.10.213

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Waller, C. F., Möbius, J., & Fuentes‐Alburo, A. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01255-z · Cited by 38 · see citing works